Abstract:Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded CAG repeat mutation in the Huntingtin ( HTT ) gene. The mutation impacts neuronal protein homeostasis and cortical/striatal circuitry. SUMOylation is a post-translational modification with broad cellular effects including via modification of synaptic proteins. Here, we used an optimised SUMO protein-enrichment and mass spectrometry method to identify the protein SUMOylation/SUMO interaction proteome in the context of HD using R6/2 transgenic and non-transgenic (NT) mice. Significant changes in enrichment of SUMOylated and SUMO-interacting proteins were observed, including those involved in presynaptic function, cytomatrix at the active zone scaffolding, cytoskeleton organization, and glutamatergic signaling. Mitochondrial and RNA-binding proteins also showed altered enrichment. Modified SUMO-associated pathways in HD tissue include clathrin-mediated endocytosis signaling, synaptogenesis signaling, synaptic long-term potentiation, and SNARE signaling. To evaluate how modulation of SUMOylation might influence functional measures of neuronal activity in HD cells in vitro , we utilised primary neuronal cultures from R6/2 and NT mice. A receptor internalization assay for the metabotropic glutamate receptor 7 (mGLUR7), a SUMO enriched protein in the mass spec, showed decreased internalization in R6/2 neurons compared to NT. siRNA-mediated knockdown of the E3 SUMO ligase Protein Inhibitor of Activated STAT1 ( Pias1 ), which can SUMO modify mGLUR7, prevented this HD phenotype. In addition, microelectrode array analysis of primary neuronal cultures indicated early hyperactivity in HD cells, while later timepoints demonstrated deficits in several measurements of neuronal activity within cortical neurons. HD phenotypes were rescued at selected timepoints following knockdown of Pias1 . Collectively, our results provide a mouse brain SUMOome resource and show that significant alterations occur within the post-translational landscape of SUMO-protein interactions of synaptic proteins in HD mice, suggesting that targeting of synaptic SUMO networks may provide a proteostatic systems-based therapeutic approach for HD and other neurological. Disorders.

Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity

SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation

Role of SUMOylation in Neurodegenerative Diseases

SUMOylation in Neurological Diseases

[Potential Involvement of Abnormal Increased SUMO-1 in Modulation of the Formation of Alzheimer's Disease Senile Plaques and Neuritic Dystrophy in APP/PS1 Transgenic Mice].

SUMO2 Protects Against Tau-induced Synaptic and Cognitive Dysfunction

Paralogue-Specific Roles of SUMO1 and SUMO2/3 in Protein Quality Control and Associated Diseases

Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum

Role of Ubiquitin–Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance

SUMOylation in brain ischemia: Patterns, targets, and translational implications

SUMOylation modulates mitochondrial dynamics in an in vitro rotenone model of Parkinson's disease

SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution

Wrestling with stress: Roles of protein SUMOylation and deSUMOylation in cell stress response

SUMOylation: A Link to Future Therapeutics.

Reduced SUMOylation of Nrf2 signaling contributes to its inhibition induced by amyloid-β

In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons

SUMO-1 Modification Increases Human SOD1 Stability and Aggregation.

Neuroinflammation and Oxidation/Nitration of Alpha-Synuclein Linked to Dopaminergic Neurodegeneration

SUMO regulation of ion channels in health and disease

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified Α-Synuclein.